Sodium‐glucose co‐transporter 2 inhibitor therapy reduces the administration frequency of anti‐vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti‐vascular endothelial growth factor agent use: A cohort study using the Japanese health insurance claims database
Authors' conclusion
There was no difference in the risk ratio for the addition of anti-VEGF therapy between the two treatment groups. However, the use of SGLT2is reduced the frequency of anti-VEGF agent administration in patients with DMO requiring anti-VEGF therapy. Therefore, SGLT2i therapy may be a novel, non-invasive, low-cost adjunctive therapy for DMO requiring anti-VEGF therapy.
Study context
- Population
- Japanese patients with diabetic macular oedema (DMO) in a health insurance claims database covering 11 million patients, 2005–2019matched
- Participants
- 2,412 patients
- Exposure
- SGLT2i users vs non-users
- Outcome
- Frequency and duration of intravitreal anti-VEGF injection after initiating SGLT2is or other antidiabetic drugs
Methodological detailsmatched, health insurance claims database
- Matched
- Health insurance claims database
Main finding
As reported in the abstract
Incidence of anti-VEGF agent injections
SGLT2i users
230.1 per 1000 person-year
Non-users
228.4 times per 1000 person-year
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Anti-VEGF injections, subgroup with history of anti-VEGF use | 0.44 (0.22–0.91) | P = 0.027 | |
| First anti-VEGF injection | 0.45 (0.22–0.91) | P = 0.023 | |
| Second anti-VEGF injection | 0.39 (0.17–0.89) | P = 0.021 | |
| 0.10.31310Hazard ratio (log scale) |
Original publication
Sodium‐glucose co‐transporter 2 inhibitor therapy reduces the administration frequency of anti‐vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti‐vascular endothelial growth factor agent use: A cohort study using the Japanese health insurance claims database. Diabetes Obes Metab. Published 19 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →